Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is a sodium channel blocker presented as an intravenous solution for intravenous use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency.

GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, providing EU‑origin products that meet stringent quality standards.

Lacosamide is an antiepileptic drug used in the management of seizure disorders.

- Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens. - Focal epilepsy: improves seizure control in patients with focal onset epilepsy. - Epilepsy (adjunctive therapy): provides additional seizure reduction for patients whose seizures are not fully controlled by other medications.

Lacosamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of lightheadedness. - Headache: mild to moderate head pain. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR interval prolongation or atrial fibrillation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.

When using Lacosamide, several precautions should be observed to ensure patient safety.

- Monitor cardiac function: obtain baseline ECG and watch for PR interval prolongation. - Assess renal function: adjust dosing in patients with severe renal impairment. - Avoid abrupt discontinuation: taper to prevent increased seizure frequency. - Use caution in hepatic impairment: monitor liver enzymes regularly. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Co‑administration with other sodium channel blockers (e.g., carbamazepine) may increase cardiac conduction effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole) can raise lacosamide plasma concentrations. - Drugs that prolong PR interval (e.g., verapamil) may cause additive cardiac effects.

Moderate Interactions (Monitor Closely): - Combination with other antiepileptics (e.g., valproate) may require dose adjustments. - Concurrent use with alcohol may enhance central nervous system depression. - Diuretics may alter electrolyte balance, influencing cardiac conduction.